Business Overview

Healthpeak Properties, Inc. (NYSE: DOC) is a real estate investment trust (REIT) focused on owning, operating, and developing real estate for the U.S. healthcare industry. The company concentrates on three property types: outpatient medical buildings (often located on or near hospital campuses), life science laboratory and office space (clustered in leading research markets such as South San Francisco, San Diego, and Boston/Cambridge), and continuing care retirement communities (CCRCs). The current company is the result of the 2024 all-stock merger of Healthpeak and Physicians Realty Trust, which expanded its outpatient medical footprint and led to the adoption of the "DOC" ticker. As a REIT, Healthpeak is generally required to distribute most of its taxable income to shareholders as dividends, and it pays little or no corporate income tax at the entity level so long as it meets REIT qualification rules.

Healthpeak makes money primarily by collecting rent from tenants under leases on its properties. In the outpatient medical and life science segments, it earns rental income plus recoveries of operating expenses (such as property taxes, insurance, and common-area costs) under net or modified-gross leases, frequently with contractual annual rent escalators. The CCRC business generates resident fees and services revenue tied to occupancy and care levels rather than pure landlord rent. The company also earns income from development and redevelopment projects, joint ventures, and interest on real estate loans. Growth comes from leasing up and developing space, acquiring properties, raising rents on renewal, and recycling capital out of lower-conviction assets into higher-quality ones.

Financial Trends

As a healthcare REIT, Healthpeak's income statement is driven mostly by rental and related revenue, partially offset by property operating expenses, large non-cash depreciation and amortization (which makes GAAP net income a poor proxy for cash earnings), interest expense, and merger/integration costs. Because depreciation is so heavy in real estate, investors should focus on REIT-specific cash-flow metrics that management reports, especially Funds From Operations (FFO), Adjusted FFO (AFFO), and same-store cash net operating income (NOI), rather than headline net income alone.

• Revenue mix and stability: Outpatient medical tends to provide steady, diversified rent from many smaller tenants; life science is higher-growth but more cyclical and tied to biotech funding and lab demand; CCRC revenue moves with senior-living occupancy and labor costs.
• Same-store NOI and occupancy: These show whether the existing portfolio is growing organically through occupancy gains, rent escalators, and re-leasing spreads.
• Capital intensity: Development pipelines, tenant improvements, and leasing commissions consume meaningful capital, so AFFO (which deducts recurring capital costs) matters for assessing the dividend.
• Balance sheet: Watch leverage (net debt to EBITDAre), the share of fixed- vs. floating-rate debt, debt maturity ladder, and liquidity, since REITs rely heavily on debt and equity markets to fund growth.
• Capital recycling: The company regularly sells assets and reinvests proceeds, so gains/losses on sales and acquisition activity can swing reported results.

What to Watch in the Filings

When reading Healthpeak's 10-K and 10-Q, focus on the disclosures that reveal the health of a landlord-heavy healthcare business:

• Segment results: Revenue, NOI, occupancy, and same-store growth broken out for outpatient medical, life science, and CCRC. Compare segment trends, since each has very different demand drivers.
• FFO/AFFO reconciliation: Found in the earnings supplement and MD&A; check management's definitions and any adjustments, plus full-year guidance ranges and revisions.
• Leasing metrics: Re-leasing spreads, lease expiration schedules, retention rates, and tenant improvement costs, which signal pricing power and re-tenanting risk, especially in life science.
• Development pipeline: Project costs to date, estimated total spend, pre-leasing percentages, and expected stabilized yields.
• Tenant concentration: Top tenants and the share of revenue they represent, plus any watch-list or credit concerns.
• Debt detail: Maturity schedule, weighted-average interest rate, fixed vs. floating mix, covenant headroom, and use of the credit facility and commercial paper.
• Merger/integration items: 8-K filings and MD&A for synergy progress, integration charges, and any remaining purchase-accounting effects from the Physicians Realty combination.
• Dividends and capital actions: 8-Ks announcing dividend declarations, buyback authorizations, and major acquisitions or dispositions.

Key Risks

• Interest-rate sensitivity: As a capital-intensive REIT, higher rates raise borrowing and refinancing costs, can pressure property values and cap rates, and make the dividend yield compete with bonds.
• Life science cyclicality: Lab demand and rents depend on biotech funding, venture capital, and the broader R&D cycle; oversupply in key markets or slower funding can hurt occupancy and re-leasing spreads.
• Tenant credit and concentration: Defaults, downsizing, or financial distress among major tenants (including biotech firms and health systems) can reduce rental income.
• Healthcare and senior-living exposure: The CCRC segment faces occupancy swings, rising labor and insurance costs, and operator/regulatory risk; broader healthcare reimbursement and policy changes can affect tenants' ability to pay rent.
• Development and lease-up risk: Projects may face construction cost inflation, delays, or weaker-than-expected pre-leasing, lowering returns on invested capital.
• Merger integration: Realizing expected synergies from the Physicians Realty combination, and integrating systems and portfolios, carries execution risk.
• REIT and tax structure: Failure to meet REIT qualification rules could trigger corporate taxation; high payout requirements also limit retained capital for reinvestment.
• Capital-markets dependence: Growth relies on access to debt and equity; tighter or more expensive capital can constrain acquisitions and development.

Frequently Asked Questions